Samba Scientific’s Post

Alzheimer’s disease diagnostics are moving toward less invasive, highly accurate, blood-based assays. Listen to Henrik Zetterberg, PhD, and Kaj Blennow, PhD, at our Feb. 28th webinar as they present clinical data for the novel ALZpath plasma pTau217 immunoassay for the accurate identification of Alzheimer’s disease pathology. Topics they will cover include: • The results obtained from Wisconsin’s Registry for Alzheimer's Prevention (WRAP) in relation to pTau217 and the practical aspects of high-throughput sample analysis • pTau217’s superior solo performance compared to pTau217/non-pTau212-221 ratio • The advancements in developing an easy- to- use, highly accurate blood-based AD test. Don’t miss out. Register for the webinar today: https://hubs.li/Q02jXqxL0 #pTau217 #Alzheimers #neuroscience #ClinicalResearch #diagnostics #biomarkers

#NEW from #AAIC2023 | Brain-body communication in #neurodegenerative diseases 🎥 🧠 Katerina Akassoglou, PhD, from the University of California, San Francisco, discusses the bidirectional relationship between the #brain and body, and its impact upon #neurodegenerativediseases 💡 Various peripheral mechanisms make the #brain more vulnerable to #neurological disease, whilst the #brain also regulates relevant processes within the body Further exploration of these communication mechanisms enhances the possibility to harness developments in #vascular #biology, #immunology, #neuroscience, and #hematology to develop novel imaging tools and therapeutics for neurological disorders 🧪🩸 Find out more 👉 https://lnkd.in/daNxqrSn #Dementia

Plasma p-tau212 antemortem diagnostic performance and prediction of autopsy verification of Alzheimer's disease neuropathology A significant advancement has been achieved in Alzheimer's Disease (AD) diagnostics through a novel blood test. Researchers have developed an innovative immunoassay specifically targeting p-tau212, a key biomarker associated with AD, distinct from similar biomarkers like p-tau217. Highlights of the Discovery: 🩸 The new blood-based assay for p-tau212 demonstrates exceptional accuracy in AD diagnosis, rivaling the performance of the well-established p-tau217 assays. 📊 Evaluated across five cohorts encompassing 388 participants, p-tau212 proved effective not only in diagnosing AD but also in detecting amyloid and tau pathologies, critical indicators of the disease. 🧪 The assay's diagnostic accuracy and the magnitude of change in p-tau212 levels surpassed those observed for other markers such as p-tau181 and p-tau231. 🧫 Detailed examinations showed significant p-tau212 presence in the neurofibrillary tangles within the brain, a key feature of AD, underscoring its role in AD pathophysiology. From Nature Communications: https://lnkd.in/gfkKFNih #HealthTech #Diagnostics #Neuroscience

In their latest publication published in EMBO Reports (PMID 38413732), Yook et al. suggest PSD-95 as an early-stage biomarker and a novel therapeutic target for Alzheimer’s disease. Using our monoclonal Homer1b/c antibody as postsynaptic marker, they were able to reveal the underlying mechanism of elevated seizure activity during early-stage Abeta pathology. https://lnkd.in/euiVbgzH #neuroscience #antibodies #Homer1bc

In the context of my presentation of paraclinical examinations and biomarkers in Multiple Sclerosis, without a doubt the role of MRI has accelerated the time to diagnosis, improving disability and cognitive outcomes. However, the cost has been decreased specificity. Thanks to the advance in the knowledge of the pathology and with the advent of the optic nerve as a spatial criterion, we must be cautious, which is why adding biomarkers both serological, such as in CSF and imaging such as CVS, CL, PRL among others, will help us in the differential diagnosis in atypical cases, in addition to the possibility of establishing a prognosis of the disease. Without a doubt, they are great advances for our patients and a challenge for clinicians. #multiplesclerosis #neuroimmunology #biomarkers #teaching

The cellular changes connecting aging and Alzheimer’s disease (AD) pathogenesis remain unclear. In their 2024 publication, Shi and colleagues found that a bone-derived osteokine known as sclerostin can bypass the blood brain barrier, enter the brain and inhibit neuronal Wnt/beta-catenin signaling. Increased levels of sclerostin in aged mice induces synaptic deficits and cognitive deficits. Moreover, increased expression of sclerostin has been observed in AD mouse models and in human patients with Alzheimer’s disease. Excitingly, antibody-mediated inhibition of sclerostin was sufficient to rescue amyloid-beta pathology and cognitive deficits in a murine pre-clinical model of Alzheimer’s disease. Their interesting results were published in Nature Metabolism. A Pubmed link and citation can be found in the comments section below. #Aging #Medicine #MedicalEducation #HealthScience #ResearchUpdate #TranslationalScience #Alzheimers #Alzheimerssupport #Neurobiology #Immunotherapy #Biopodia

Nasal Delivery of Tau-Specific Antibody Ameliorates Tauopathy Tau pathology is a common hallmark of neurodegenerative diseases such as Alzheimer's disease and frontotemporal dementia, yet selectively targeting toxic tau remains a significant challenge. Researchers have developed a conformation-specific antibody that preferentially binds to toxic tau aggregates. This antibody demonstrated selective engagement with toxic tau aggregates in patient-derived tissue and tau oligomers in vitro. When encapsulated in lipid-based micelles, the antibody efficiently crossed the blood-brain barrier following intranasal administration in a mouse model of tauopathy. Importantly, this treatment ameliorated tau pathology and improved cognitive function. These findings suggest a promising immunotherapeutic approach for neurodegenerative diseases characterized by tau pathology. The manuscript and a commentary about it were published in STI: https://lnkd.in/ekPgSKjw and https://lnkd.in/eGQjv5Bm. #genetics #genomics #precisionmedicine #genomicmedicine #brain #neurology #neuroscience #neurodegeneration #alzheimer #ftd #taupathology #lipidnanoparticle #antibody #immunology #immunity #tau #drugdevelopment #drugdiscovery #drugadministration #pharmacology #therapeutics #biotechnology #innovation #research #science #sciencecommunication

"Toxic" is an adjective attributed to virtually all brain proteins linked to neurodegenerative diseases. Can we name one protein that doesn't have a schizophrenic second life in the neurological literature? A protein that is acknowledged for its normal functions until it turns harmful when clumped into aggregates? Anti-tau strategies (by any route, even intranasal) are as unlikely to yield meaningful benefits as anti-synuclein, anti-amyloid, anti-SOD1, and anti-Huntingtin strategies before it. The assumption that proteins are toxic has skewed research in all areas of neurodegeneration. We have an insatiable appetite for anti-protein strategies but no interest in restoring proteins to their normal, healthy state.

This innovative study uses a specific antibody administered non-invasively to precisely and efficiently treat tauopathy, improving cognitive function and opening new perspectives for the treatment of neurodegenerative diseases. May more innovative and promising studies like this follow. Love it

Gain new insights into Alzheimer's disease research with our application note. Explore the use of Thermo Scientific Volumescope SEM and Amira Software to visualize changes in neuron morphology resulting from MCI inhibition. Learn how Amira Software streamlines data processing and enables efficient analysis. Read the full application note here. #AlzheimersResearch #Neuroscience